[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2097905T3 - Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres. - Google Patents

Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.

Info

Publication number
ES2097905T3
ES2097905T3 ES92905338T ES92905338T ES2097905T3 ES 2097905 T3 ES2097905 T3 ES 2097905T3 ES 92905338 T ES92905338 T ES 92905338T ES 92905338 T ES92905338 T ES 92905338T ES 2097905 T3 ES2097905 T3 ES 2097905T3
Authority
ES
Spain
Prior art keywords
treatment
therapeutic agents
drug resistance
cancer multi
dihydrocinchonine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92905338T
Other languages
English (en)
Inventor
Bruno Chauffert
Philippe Genne
Gilles Gutierrez
Rolland-Yves Mauvernay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm SA
Patrinove
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Debiopharm SA
Patrinove
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH57691A external-priority patent/CH682050A5/fr
Priority claimed from CH352291A external-priority patent/CH683238A5/fr
Application filed by Debiopharm SA, Patrinove, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Debiopharm SA
Application granted granted Critical
Publication of ES2097905T3 publication Critical patent/ES2097905T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE UTILIZA CINCONINA, DIHIDROCINCONINA O HIDROCINCONINA COMO SUSTANCIA INHIBIDORA DE LA RESISTENCIA MULTIDROGA EN EL TRATAMIENTO DE TUMORES CANCEROSOS MEDIANTE AGENTES CITOTOXICOS. EN PARTICULAR SE UTILIZA LA CINCONINA, LA DIHIDROCINCONINA O LA HIDROCINCONINA EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS DESTINADAS AL TRATAMIENTO DE TUMORES CANCEROSOS QUE DESARROLLAN EL FENOMENO DE LA RESISTENCIA MULTIDROGA. APLICACION EN EL TRATAMIENTO DE LOS CANCERES EN EL HOMBRE.
ES92905338T 1991-02-25 1992-02-24 Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres. Expired - Lifetime ES2097905T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH57691A CH682050A5 (en) 1991-02-25 1991-02-25 Use of cinchonine, di:hydro:cinchonine or hydro:quinidine
CH352291A CH683238A5 (fr) 1991-12-02 1991-12-02 Hydroquinidine, comme agent thérapeutique et son utilisation dans une composition pharmaceutique.

Publications (1)

Publication Number Publication Date
ES2097905T3 true ES2097905T3 (es) 1997-04-16

Family

ID=25685005

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92905338T Expired - Lifetime ES2097905T3 (es) 1991-02-25 1992-02-24 Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.

Country Status (9)

Country Link
US (1) US5635515A (es)
EP (1) EP0526608B1 (es)
JP (1) JPH06505991A (es)
AT (1) ATE146361T1 (es)
AU (1) AU649787B2 (es)
CA (1) CA2081343C (es)
DE (1) DE69215999T2 (es)
ES (1) ES2097905T3 (es)
WO (1) WO1992014467A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5866699A (en) * 1994-07-18 1999-02-02 Hybridon, Inc. Oligonucleotides with anti-MDR-1 gene activity
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
FR2764509A1 (fr) 1997-06-11 1998-12-18 Debiopharm Sa Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
FR2784580B1 (fr) * 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
BR0213989A (pt) * 2001-11-07 2005-03-01 Pharmacia Corp Métodos para promover a absorção e acúmulo nuclear de poliamidas em células eucarióticas
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2008105872A1 (en) * 2007-02-28 2008-09-04 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors
US10420761B2 (en) * 2013-03-15 2019-09-24 University Of Florida Research Foundation, Inc. Allosteric inhibitors of thymidylate synthase
EP3104859A1 (en) * 2014-02-12 2016-12-21 Adam Mickiewicz University Application of cinchona alkaloid derivatives as cytotoxic compounds
CN105796558A (zh) * 2014-12-31 2016-07-27 天津大学 辛可宁在制备抗肿瘤药物的用途
US10835524B2 (en) 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
US11066421B1 (en) 2021-02-09 2021-07-20 Ares Pharmaceuticals, LLC Synthetic cinchona alkaloids against cancer
US11649232B2 (en) 2021-05-10 2023-05-16 Ares Pharmaceuticals, LLC Synthetic dimeric cinchona alkaloids against cancer
WO2023177376A2 (en) * 2022-03-17 2023-09-21 Mugla Sitki Kocman Universitesi Idari Mali Isler Baskanligi The use of the molecule hydroquinidine in the treatment of brain tumors
WO2023230702A1 (en) * 2022-06-03 2023-12-07 University Of Manitoba Novel antimicrobial compounds isolated using a machine learning model trained on a high-throughput antibacterial screen

Also Published As

Publication number Publication date
WO1992014467A1 (fr) 1992-09-03
AU649787B2 (en) 1994-06-02
CA2081343C (fr) 2003-09-16
AU1206292A (en) 1992-09-15
DE69215999D1 (de) 1997-01-30
CA2081343A1 (fr) 1992-08-26
US5635515A (en) 1997-06-03
DE69215999T2 (de) 1997-07-03
ATE146361T1 (de) 1997-01-15
EP0526608B1 (fr) 1996-12-18
EP0526608A1 (fr) 1993-02-10
JPH06505991A (ja) 1994-07-07

Similar Documents

Publication Publication Date Title
ES2097905T3 (es) Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
BRPI0515745A (pt) imunoconjugados de antiintegrina, métodos e usos
AR020019A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
AR012172A2 (es) Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
RU93051543A (ru) Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
BR0115162A (pt) Tratamentos antitumorais eficazes
DK1017675T3 (da) Stærkt lipofile camptothecinderivater
MX9307011A (es) Derivados hidrosolubles de camptotecina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
IT1238231B (it) Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
ME00056B (me) Kombinacija kombrestatina i anti-kancer agensa
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
IT1241079B (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
ES2192878T3 (es) 4,5-azolo-oxindoles.
UY26498A1 (es) Pirroles sustituidos
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526608

Country of ref document: ES